Market Newsdesk

SHANGHAI, China, April 07, 2021 (GLOBE NEWSWIRE) — Beyond Meat, Inc. (NASDAQ: BYND), a global plant-based protein company, today announced the grand opening of its new state-of-the-art manufacturing facility in the Jiaxing Economic & Technological Development Zone (JXEDZ) near Shanghai. As Beyond Meat’s first end-to-end manufacturing facility outside the U.S., the cutting-edge plant in Jiaxing is expected to significantly increase the speed and scale in which the company can produce and distribute its products within the region while also improving Beyond Meat’s cost structure and sustainability of operations.

Designed to serve China’s growing plant-based meat market, the facility will produce Beyond Meat’s innovative range of plant-based pork, beef and poultry products, including Beyond Pork™, the company’s first innovation created specifically for the Chinese market. By producing closer to the consumer and leveraging local supply chains, Beyond Meat is investing in the growth of the plant-based meat category in China and the facility underscores the company’s commitment to China as a region for long-term growth. In addition to scaled production to support the company’s expanding retail and foodservice business within China, the facility will also feature R&D capabilities to create unique product offerings and support Beyond Meat’s local strategic partners.

“The opening of our dedicated plant-based meat facility in China marks a significant milestone in Beyond Meat’s ability to effectively compete in one of the world’s largest meat markets. We are committed to investing in China as a region for long-term growth, and we believe this new manufacturing facility will be instrumental in advancing our pricing and sustainability metrics as we seek to provide Chinese consumers with delicious plant-based proteins that are good for both people and planet,” said Ethan Brown, CEO and Founder of Beyond Meat.

The announcement comes just one year after the company first entered mainland China through a nationwide partnership with Starbucks China. Within its first year in the market, Beyond Meat has expanded menu offerings at Starbucks China and has partnered with well-known foodservice and retail brands including KFC, Pizza Hut, Jindingxuan, GangLi Beijing, Slow Boat Brewery, Hema, METRO China and more. The facility is intended to pave the way for Beyond Meat to efficiently scale-up to meet future needs and demand.

“The plant-based meat market in China continues to expand and Beyond Meat has been enthusiastically met by local consumers who are looking to live a healthy and sustainable lifestyle. The opening of the new Jiaxing plant is expected to enable us to quicken the pace of innovation and roll out our products at the speed and scale needed to remain highly competitive within the region,” said Candy Chan, General Manager for Beyond Meat in China.

Beyond Meat’s strict ingredient guardrails and commitment to making products utilizing simple, plant-based ingredients without GMOs has enabled the brand to expand product distribution throughout China and around the globe with ease and speed. In addition to the opening of the new manufacturing facility in the JXEDZ region, Beyond Meat will also be opening its first owned manufacturing facility in Europe this year in an effort to make plant-based meat more accessible to all.

U.S. Media contact:

Shira Zackai
[email protected]

China Media contact:

[email protected] 

About Beyond Meat

Beyond Meat, Inc. (NASDAQ: BYND) is one of the fastest growing food companies in the United States, offering a portfolio of revolutionary plant-based meats made from simple ingredients without GMOs, bioengineered ingredients, hormones, antibiotics, or cholesterol. Founded in 2009, Beyond Meat products are designed to have the same taste and texture as animal-based meat while being better for people and the planet. Beyond Meat’s brand commitment, Eat What You Love™, represents a strong belief that there is a better way to feed our future and that the positive choices we all make, no matter how small, can have a great impact on our personal health and the health of our planet. By shifting from animal-based meat to plant-based meat, we can positively impact four growing global issues: human health, climate change, constraints on natural resources and animal welfare. As of December 31, 2020, Beyond Meat had products available at approximately 122,000 retail and foodservice outlets in over 80 countries worldwide. Visit www.BeyondMeat.com and follow @BeyondMeat, #BeyondBurger and #GoBeyond on Facebook, Instagram and Twitter and @BeyondMeatOfficial on TikTok.

Beyond Meat Forward Looking Statements

Certain statements in this release constitute “forward-looking statements.” These statements are based on management’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward-looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While Beyond Meat believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cause actual results to differ materially from forward-looking statements made herein including, most prominently, the risks discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 1, 2021 as well as other factors described from time to time in Beyond Meat’s filings with the SEC. Such forward-looking statements are made only as of the date of this release. Beyond Meat undertakes no obligation to publicly update or revise any forward-looking statement because of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.

 

CAMBRIDGE, United Kingdom, April 07, 2021 (GLOBE NEWSWIRE) — Biofidelity Ltd, the cancer diagnostics company, today announced that it has been granted a key patent in the US protecting its underlying technology.  The grant of US patent US20200354786 has confirmed the novelty and inventiveness of its technology, which is designed to break down barriers to better screening, monitoring and treatment of cancer through ultra-sensitive detection of the key tumor markers recommended in treatment guidelines.

It combines fast, easy-to-interpret results with affordability, enabling oncologists to make precise decisions earlier, monitor resistance and track disease recurrence. Biofidelity expects to launch its first product, Identi-Lung, for the detection of non-small cell lung cancer, later this year.

Dr. Barnaby Balmforth, Chief Executive Officer of Biofidelity, commented: “The grant of this key patent in the US is another important step forward in our goal of transforming diagnosis to make sure every cancer patient receives the right drug at the right time. We are working hard to build a comprehensive portfolio of IP protecting our technology, applications and products to enable any lab to offer high quality precision cancer diagnostics.”

About Biofidelity

Biofidelity, a private company founded in 2019 in Cambridge, UK, is revolutionizing access to best-in-class cancer diagnostics, breaking down the barriers to better screening, monitoring and treatment for all cancer patients.  Its disruptive diagnostic technology platform will provide oncologists with clinically actionable data based on ultra-sensitive detection of markers recommended in cancer treatment guidelines, enabling them to prescribe the right cancer drug at the right time.  It is designed to combine fast and easy-to-interpret results with affordability and straightforward adoption on existing laboratory infrastructure, enabling many more laboratories to offer high quality cancer diagnostics. Biofidelity is initially focusing on diagnosis of non-small cell lung and colorectal cancer, with potential in a broad range of cancers and medium- to long-term applications in the detection of resistance to therapy and disease recurrence.

For more information, please go to  www.biofidelity.com

For enquiries, please contact:

Biofidelity Dr Barnaby Balmforth, CEO T: +44 1223 358652 E: [email protected]

Mo PR Advisory Mo Noonan/ Jonathan Birt Tel: +44 (0) 7876 444977 / (0) 7860 361746

Press Release

Nokia and Lenovo conclude patent cross-licensing agreement

7 April 2021

Espoo, Finland – Nokia and Lenovo conclude patent cross-licensing agreement.

Nokia announced today that it has concluded a multi-year, multi-technology patent cross-license agreement with Lenovo. Under the agreement, Lenovo will make a net balancing payment to Nokia. The terms of the agreement remain confidential. The agreement resolves all pending patent litigation and other proceedings between the two parties, in all jurisdictions.

Jenni Lukander, President of Nokia Technologies, said: “We are delighted to have reached an agreement with Lenovo. The agreement reflects Nokia’s decades-long investments in R&D and contributions to cellular and multimedia standards. We appreciate, and very much respect, the constructive spirit Lenovo brought to our negotiations and look forward to working together to bring further innovation to their users around the world.”

John Mulgrew, Chief Intellectual Property Officer of Lenovo, commented: 

“Our agreement with Nokia reflects the value of both Nokia’s technology leadership and Lenovo’s continued investment in 5G innovation.  The global accord struck will enable future collaboration between our companies for the benefit of customers worldwide.”

Nokia’s industry-leading patent portfolio is built on more than €129 billion invested in R&D over the past two decades and is composed of around 20,000 patent families, including over 3,500 patent families declared essential to 5G.

In addition to its leadership in cellular standards, Nokia has also contributed significantly to multimedia and video research and the development of industry standards over the course of more than 30 years.

Nokia contributes these and other inventions to open standards in return for the right to license them on fair, reasonable and non-discriminatory (FRAND) terms. Companies can license and use these technologies without the need to make their own substantial investments in R&D.

Additional resources

·Webpage:  Licensing https://www.nokia.com/licensing/

About Nokia

We create technology that helps the world act together. As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks. We create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs. Adhering to the highest standards of integrity and security, we help build the capabilities needed for a more productive, sustainable and inclusive world.

For our latest updates, please visit us online www.nokia.com and follow us on Twitter @nokia.

About Lenovo

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$50 billion Fortune Global 500 company, with 63,000 employees and operating in 180 markets around the world.  Lenovo’s nearly 10,000 R&D employees have generated over 20,000 patents across a wide range of technologies, including computing, telecommunications, and artificial intelligence.  Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that create a more inclusive, trustworthy and sustainable digital society. By designing, engineering and building the world’s most complete portfolio of smart devices and infrastructure, we are also leading an Intelligent Transformation – to create better experiences and opportunities for millions of customers around the world.  To find out more visit https://www.lenovo.com, follow us on LinkedIn, Facebook, Twitter, YouTube, Instagram, Weibo and read about the latest news via our StoryHub.

Media Inquiries:

Nokia
Communications
Phone: +358 10 448 4900
Email: [email protected]

Lenovo
Phone : +44 7825 605720
Email : [email protected]

Sydney, April 07, 2021 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

• Alta Zinc Ltd (ASX:AZI) (FRA:8EE) has received thick, high-grade zinc and lead results from the first drill pad of its maiden drilling program at Ponente area of the Gorno Project in Italy with added silver. Click here
• Auteco Minerals Ltd’s (ASX:AUT) (OTCMKTS:MNXMF) strategy to upgrade and grow the 1-million-ounce inferred resource at its Pickle Crow Gold Project in Canada continues to deliver strong results with the discovery of more high-grade mineralisation. Click here
• Perseus Mining Ltd (ASX:PRU) (TSE:PRU) (OTCMKTS:PMNXF) (FRA:P4Q) has demonstrated potential for organic growth of gold inventories across its multi-mine asset portfolio in Côte d’Ivoire with further broad high-grade results from regional drilling at Sissingué and Yaouré. Click here
• K2fly Ltd (ASX:K2F) experienced a record invoicing quarter, with A$2.06 million in invoices raised in the March quarter, a 28% increase on the A$1.61 million of the corresponding quarter of FY20. Click here
• Miramar Resources Ltd (ASX:DRM) has kicked off drilling at its highly prospective gold projects in world-class locations and is progressing various other projects through permitting and or tenement grant. Click here
• CV Check Ltd (ASX:CV1) has completed the acquisition of CI6 Pty Ltd an entity that owns Bright People Technologies Pty Ltd (BPT), a SaaS cloud-based provider of workforce credentials and compliance software through the Enable and Cited brands. Click here

About Proactive  

With six offices on three continents and a team of experienced business journalists and broadcasters, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives engage intelligently with investors.

Proactive’ s platform delivers the right message to the right audience, digitally and in real time, leveraging a range of media, investment research, digital investor targeting and website development services to support over 1,000 fast-growing companies globally.

Proactive’s network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.

•           Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.
•           We syndicate our content to hundreds of mainstream and specialist news sites that expand our reach into networks that can be difficult for press releases to penetrate.
•           We custom build corporate websites from the ground up, empowering clients and their brands with a modern online presence and the latest insight on effective SEO strategy.
•           Our news coverage ranks high on the world’s most popular search platforms, and we can further amplify online presence and outreach with sophisticated digital investor targeting.
•           We help the world understand what makes companies stand out from the crowd with in-depth investment research from a team of experienced analysts.

For more information on how Proactive can help you make a difference, email us at [email protected]

Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines  

• Launch of a new and more impactful global corporate social responsibility strategy
• Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity and inclusion
• Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world’s poorest countries access to 30 essential medicines

PARIS – April 7, 2021 – In an open letter, Sanofi Chief Executive Officer Paul Hudson today outlined several key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. Embedded in Sanofi’s long-term strategy, the company’s commitment is based on four essential pillars in which Sanofi is uniquely positioned to make a difference: access to medicines, support for vulnerable communities, preservation of the environment, and inclusion and diversity of its employees.

“The pandemic has forced us to question nearly every aspect of our lives: how we live and work, and how we connect with our communities and the planet. Yet as challenging as 2020 was, it also brought us –Sanofi and the pharmaceutical industry– closer to our purpose than at any other time in living memory,” said Hudson. “This unique context led us to elevate our ambition for our Corporate Social Responsibility strategy and embed it even more into our mission to transform lives and our vision for a better future.”

Sanofi Global Health, pillar of access to essential medicines

A cornerstone of Sanofi’s CSR strategy, Sanofi Global Health is a newly formed nonprofit unit within the company. Leveraging the company’s diverse and large portfolio of medicines and global footprint, Sanofi Global Health is dedicated to increasing access to medicines considered essential by the World Health Organization (WHO) for patients in 40 lower income countries. Thirty of Sanofi’s medicines will be provided across a wide range of therapeutic areas, including cardiovascular disease, diabetes, tuberculosis, malaria and cancer. Sanofi Global Health will also fund the training of healthcare professionals or the set up and development of sustainable care systems for those who suffer from chronic diseases and require complex care.

Sanofi Global Health is the first global initiative to provide access to such a broad portfolio of medicines, in so many countries and across several therapeutic areas, while funding local support programs.

Additionally, Sanofi is committed to helping 1,000 patients living with rare diseases who have no access to treatments and will donate 100,000 vials of medicine for their treatments each year. This continues Sanofi’s 30-year commitment to patients suffering from rare diseases, such as Fabry, Gaucher or Pompe diseases, for which access to treatment is often limited.

Leveraging R&D efforts to address crucial treatment gaps

Sanofi continues to support vulnerable communities and commits to developing innovative medicines for pediatric cancer, with the ultimate ambition of eliminating cancer deaths in children. In low- to middle-income countries, a child is four times more likely to die of pediatric cancers than children living in high-income countries.

Sanofi also continues its efforts to fight polio and sleeping sickness, two of its historical programs that address global health issues. In December 2020, Sanofi announced it had renewed its five-year partnership with WHO to fight neglected tropical diseases that affect approximately one billion people. In this context, Sanofi, the only pharmaceutical company that keeps developing and supplying treatments for African trypanosomiasis or sleeping sickness, has committed itself alongside the WHO to eliminate this neglected tropical disease in humans by 2030. For 40 years, Sanofi has supplied billions of polio vaccine doses, including hundreds of millions of donated doses to support the global polio eradication effort.

Zero plastic packaging for vaccines and ecodesign of products

For several years, Sanofi has been implementing a global environmental protection program, Planet Mobilization. Today, the company is amplifying its actions to further improve the environmental footprint of its products and activities.

To reduce its greenhouse gas emissions by 55% by 2030 and contribute to better resource conservation, Sanofi plans to remove all pre-formed plastic packaging (blister packs) for its vaccines by 2027. The company is also committed to ecodesigning all its new products by 2025. In terms of energy management, all Sanofi sites will use 100% renewable electricity and the company has set a target of a carbon-neutral car fleet, both by 2030.

Pushing to build more diverse and inclusive workforce

As a global company, Sanofi is committed to ensuring that its leaders reflect the communities and patients it serves. The company is committed to building an organization where all employees have equal opportunities to reach positions of responsibility within the company. Sanofi will continue to build a workforce that is fully reflective of the communities employees live in and the patients the company serves. This element of the social impact strategy will be integrated into the career development of Sanofi leaders worldwide, ensuring a mindset that fosters diversity and inclusion throughout the company.
             

“Throughout this pandemic, public authorities, scientists, and industry have worked closely together to discover and produce vaccines at a pace that has defied historical precedent. We now have to apply this same sense of urgency to other pressing threats, such as climate change, and issues that the pandemic has sharply put into focus, including widening racial and healthcare inequalities. Let’s always remember that crises do not just neatly follow one after the other, they stack up. At Sanofi, we know we can do more,” said Hudson.

About Sanofi   Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.   With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.   Sanofi, Empowering Life
Media Relations Contact Ashleigh Koss Tel: +1 (908) 981-8745 [email protected]   Sandrine Guendoul Tel.: +33 (0) 6 25 09 14 25 [email protected]	Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine   Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco   IR main line: Tel.: +33 (0)1 53 77 45 45 [email protected]   https://www.sanofi.com/en/investors/contact
Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  Any material effect of COVID-19 on any of the foregoing  could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements

 

 

Attachment

• Press release

HAMILTON, Ontario, April 07, 2021 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global telemedicine company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed a new contract with its first Orthopedic Practice in Texas and, in response to significant market demand, has expanded its iUGO Care platform to allow Orthopedic Specialists to manage their chronic orthopedic and post-operative patients at home.

“As the vaccine rollout successfully proceeds in the United States, we are very pleased to see our clients moving forward with patient onboarding at a steadily increasing pace,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “Now that clinicians in the US are able to return their focus to proactive patient care, we’re experiencing significant new demand for deployment of our existing solutions as well as requests for new features. We are excited to launch our newest iUGO Care module, designed to support Orthopedic Specialists who want to monitor both their chronic patients (e.g. those living with rheumatoid arthritis, osteoarthritis, osteoporosis, etc.) and their post-operative patients at home. According to the CDC, there are over 5.7 Million arthritis patients in Texas alone, representing a large and growing new target market segment for Reliq. Using iUGO Care to provide Remote Patient Monitoring (RPM), Chronic Care Management (CCM), Principal Care Management (PCM) and Behavioural Health Integration (BHI) services to chronic orthopedic patients can help improve medication adherence, increase compliance with prescribed physiotherapy exercises and reduce the depression and anxiety often seen in chronic pain patients, significantly enhancing their quality of life.”

Leveraging the existing Medicare and Medicaid billing codes, Orthopedic practices can generate over $500,000 per year in new billings by providing RPM, CCM, PCM and BHI services to their patients. Reliq expects to begin onboarding orthopedic patients under this contract in April, at an average revenue of $50 USD per patient per month.

Reliq Health

Reliq Health Technologies is a rapidly growing global telemedicine that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB.

ON BEHALF OF THE BOARD
“Dr. Lisa Crossley”
CEO and Director

For further information please contact:

Company Contact

Investor Relations at [email protected]

US Investor Relations Contact

Investor Relations
Lytham Partners, LLC
Ben Shamsian
New York | Phoenix
646-829-9701
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the “Company“) does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.